Determining the optimal sequencing of bispecifics and CAR-T cells in multiple myeloma

Bispecific antibodies and CAR-T cells have transformed the myeloma treatment landscape in recent years, providing hope for patients with relapsed/refractory (R/R) disease. While both of these therapies offer benefits to patients, there are challenges to address regarding the optimal sequencing of these agents.

In this podcast, experts Salomon Manier, MD, PhD, Lille University Hospital, Lille, France, Surbhi Sidana, MD, Stanford University, Stanford, CA, and Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, share some interesting insights into the optimal sequencing of bispecific antibodies and CAR-T cells in myeloma, highlighting data from recent clinical trials.